부산대학교 도서관

This article presents a study focusing on the usefulness of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, as an additional aid in the standard treatment of patients with metastatic clear-cell renal cell carcinoma (RCC). The study incorporated a clinical trial which examined patients treated with sunitinib malate during the progression of their disease. Researchers examined the development of tumors and monitored the survival rate of the controlled group. The study found that sunitinib malate was almost uniformly successful in RCC and resulted in only minor side-effects for a small percentage of these patients.